Pancreas is one of the major endocrine gland which secretes hormones released directly into the blood. Pancreas is around 6 inches long located in the abdominal cavity. Pancreas produce the vital hormones of insulin, pancreatic polypeptide, glucagon and somatostatin. Pancreas aid in digestion and absorption processes by secreting the pancreatic juice which contains digestive enzymes. The Artificial Pancreas Device System is used in the treatment of Type 1 Diabetes. Type 1 diabetes patients require multiple doses of insulin in a day and all-round the year. The Artificial Pancreas Device System is also referred to as the closed-loop system or autonomous system for glycemic control or bionic pancreas. The Artificial Pancreas Device System simulates the glucose regulation function of a healthy pancreas. The continuous glucose monitoring is done by placing the sensor subcutaneously to measure the glucose level in the fluid around the cells. A transmitter sends information of glucose level estimates and their rate of change to the receiver. Control algorithm software embedded in an external controller performs mathematical calculations to send dosing instruction to the insulin infusion pumps, computer or smartphone. Depending on the dosing instructions, the insulin infusion pump regulates the level of insulin delivery to the subcutaneous tissue.
Browse Full Report@ http://www.futuremarketinsights.com/reports/artificial-pancreas-device-system-market
Artificial Pancreas Device System Market: Drivers & Restraints
The Food and Drug Administration (FDA) is collaborating with private and government research institutions to improvise clinical studies and accelerate the development of the Artificial Pancreas Device Systems. In October 2012, the FDA released a document on requirements of clinical studies and premarket approval applications for the production Artificial Pancreas Device Systems. This will encourage the manufacturing of Artificial...